Strong Quarterly and Full‑Year Revenue Growth
Q4 product revenue of $1.5B, up 32% year‑over‑year; Q4 BRUKINSA revenue $1.1B, up 38% YoY. Full‑year 2025 BRUKINSA global revenues of $3.9B, up 49% YoY.
BeOne Medicines
· ONC
February 26th, 2026
Summary
- Earnings Call Date:
- 2026-02-26
- Change Since:
- -14.59%
- Next Earnings Date:
- 2026-08-21
Earnings Call Sentiment
PositiveThe call presents a strongly positive commercial and R&D narrative: robust revenue and margin expansion, GAAP profitability, substantial free cash flow, BRUKINSA’s clear commercial leadership backed by best‑in‑class long‑term data, multiple regulatory wins and rapid pipeline advancement. Notable risks discussed include safety/efficacy concerns with some fixed‑duration competitor regimens, competitive dynamics that require longer follow‑up, one‑time accounting/tax items and elevated operating investment for 2026. On balance the financial strength, clinical momentum and strategic pipeline depth outweigh the operational and competitive uncertainties noted.
Company Guidance
BeOne guided 2026 revenues of $6.2–$6.4 billion, expecting continued global BRUKINSA leadership, stable U.S. net pricing and modest initial contributions from sonrotoclax and zanidatamab, with GAAP gross margin forecast in the high‑80% range; GAAP operating expenses are projected at $4.7–$4.9 billion, implying GAAP operating income of $700–$800 million and non‑GAAP operating income of $1.4–$1.5 billion, other income/expense expected to be a $25–$50 million expense (including interest on the Royalty Pharma arrangement), and management asked analysts to model similar Q1 2026 shipping‑week seasonality to Q1 2025 while noting a possible, but timing‑uncertain, partial reversal of valuation allowance that could generate a material tax benefit when recognized.
Profitability and Cash Generation
GAAP net income of $287M for 2025 (GAAP diluted EPS $2.53); non‑GAAP net income $918M (non‑GAAP diluted EPS $8.09). Free cash flow > $940M for FY2025 and $380M in Q4.
Improved Margins and Operational Leverage
Gross margin improved to 87% from ~84% a year earlier, driven by favorable product mix, pricing and cost efficiencies.
BRUKINSA: Commercial Leadership and Best‑in‑Class Data
BRUKINSA is #1 in the U.S. and globally. Long‑term data presented at ASH 2025 show 6‑year PFS ~74% (77% COVID‑adjusted) and OS ~84% (87% adj). ALPINE head‑to‑head PFS hazard ratio 0.69 (p=0.001) versus ibrutinib.
Ambitious 2026 Financial Guidance
Management projects 2026 revenue of $6.2B–$6.4B, GAAP operating income $700M–$800M, and non‑GAAP operating income $1.4B–$1.5B; GAAP gross margin expected in the high‑80% range.
R&D Momentum and Regulatory Progress
First global approvals for sonro in China for relapsed/refractory MCL and CLL; U.S./EU submissions for relapsed/refractory MCL under review with FDA approval expected in H1. BTK degrader program advanced with 3 Phase III studies initiated (including a head‑to‑head vs pirtobrutinib). TEVEMBRA delivered a positive Phase III readout in HER2+ gastric cancer (with zanidatamab + chemo).
Multiple Proofs‑of‑Concept and Clinic Starts
Five assets achieved clinical proof‑of‑concept in 2025 and ~17 new molecular entities entered the clinic over the past two years, demonstrating sustained pipeline productivity.
Industry‑Leading Clinical Execution Speed
Completed ~200 dose‑escalation cohorts with median 1.5 months per cohort (industry ~3 months). CELESTIAL TN CLL enrolled ~700 patients across 20 countries and 200+ sites in 14 months. NDA filing for sonro completed within 1 month of top‑line data (vs industry 4–6 months).
Geographic and Portfolio Expansion
Strong geographic growth: U.S. Q4 sales ~$850M (38% YoY growth), China Q4 revenue $399M (11% YoY), Europe Q4 $174M (53% YoY), Rest of World up 74% YoY. Early launches for zanidatamab and sonrotoclax expected to contribute modestly in 2026.
Operator
Good day, everyone. Welcome to BeOne Medicines Q4 and Full Year 2025 Earnings Call. [Operator Instructions] At this time, I would like to turn the call over to the company.
Daniel Maller
Hello, and welcome. Thanks for joining us today. I'm Dan Maller, Head of Investor Relations at BeOne Medicines. Before we begin, please note that you can find additional materials, including a replay of today's webcast and presentation on the Investor Relations section of our website, ir.beonemedicines.com. I would like to remind all participants that during this call, we may make forward-looking statements regarding, among other things, the company's future prospects and business strategy. Actual results may differ materially from those indicated in the forward-looking statements as a result of various factors, including those risks discussed in our most recent periodic report filed with the SEC. Please also carefully review the forward-looking statements disclaimer in the slide deck that accompanies this presentation. Reconciliations between GAAP and non-GAAP financial measures discussed on this call are provided in the appendix to our presentation, which is posted to our Investor Relations website along with our earnings release.
And all information in this presentation is as of the date of this presentation, We undertake no duty to update such information unless required by law. Now turning to today's call as outlined on Slide 3. John Oyler, our Co-Founder, Chairman and CEO, will provide a business update, including commentary on our foundational CLL franchise; Aaron Rosenberg, our CFO, will provide ...
Subscribe to unlock transcripts
Get The Fly Pro 7 days for free